1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 74, 2023
  5. Article

Annual Review of Medicine

Volume 74, 2023

Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss

Abstract

Chimeric antigen receptor (CAR) modified T cell therapy has transformed the management of relapsed/refractory B cell malignancies. Despite high overall response rates, relapse post CAR T treatment remains a clinical challenge. Loss of target antigen, specifically CD19, is one well-defined mechanism of disease relapse. The mechanism of CD19 loss and which patients are at higher risk of CD19 loss remain poorly understood. To overcome CD19 loss, CARs targeting multiple antigens are being tested in clinical trials. CD19/20 and CD19/22 bispecific CARs demonstrate cytotoxicity against CD19-negative cells in preclinical studies. These CARs have also shown efficacy, safety, and a relatively low rate of CD19-negative relapse in phase I trials. These small studies suggest that multispecific CAR T cells can deprive lymphomas of escape via antigen loss. However, the selection of an ideal target, the right CAR construct, and whether these multispecific CARs can induce long-term remissions are still under investigation.

Keyword(s): antigen loss, bispecific CAR, chimeric antigen receptor modified T cell therapy, lymphoma, trispecific CAR
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042921-024719
2023-01-27
2024-04-29
Loading full text...

Full text loading...

/deliver/fulltext/med/74/1/annurev-med-042921-024719.html?itemId=/content/journals/10.1146/annurev-med-042921-024719&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Eshhar Z, Waks T, Gross G, Schindler DG. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. PNAS 90:720–24
     [Google Scholar]
  2. 2.
    Zhang C, Liu J, Zhong JF, Zhang X. 2017. Engineering CAR-T cells. Biomark. Res 5:22
     [Google Scholar]
  3. 3.
    Maher J, Brentjens RJ, Gunset G et al. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20:70–75
     [Google Scholar]
  4. 4.
    Brentjens RJ, Latouche JB, Santos E et al. 2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9:279–86
     [Google Scholar]
  5. 5.
    Maude SL, Laetsch TW, Buechner J et al. 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378:439–48
     [Google Scholar]
  6. 6.
    Neelapu SS, Locke FL, Bartlett NL et al. 2017. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377:2531–44
     [Google Scholar]
  7. 7.
    Wang M, Munoz J, Goy A et al. 2020. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382:1331–42
     [Google Scholar]
  8. 8.
    Jacobson CA, Chavez JC, Sehgal A et al. 2021. Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24). J. Clin. Oncol. 39:7515
     [Google Scholar]
  9. 9.
    Locke FL, Miklos DB, Jacobson CA et al. 2022. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386:640–54
     [Google Scholar]
  10. 10.
    Bishop MR, Dickinson M, Purtill D et al. 2022. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386:629–39
     [Google Scholar]
  11. 11.
    Park JH, Riviere I, Gonen M et al. 2018. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378:449–59
     [Google Scholar]
  12. 12.
    Shah NN, Lee DW, Yates B et al. 2021. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J. Clin. Oncol. 39:1650–59
     [Google Scholar]
  13. 13.
    Chong EA, Ruella M, Schuster SJ et al. 2021. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 384:673–74
     [Google Scholar]
  14. 14.
    Chow VA, Gopal AK, Maloney DG et al. 2019. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am. J. Hematol. 94:E209–13
     [Google Scholar]
  15. 15.
    Cheng J, Zhao L, Zhang Y et al. 2019. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front. Oncol. 9:1237
     [Google Scholar]
  16. 16.
    Orlando EJ, Han X, Tribouley C et al. 2018. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24:1504–6
     [Google Scholar]
  17. 17.
    Sotillo E, Barrett DM, Black KL et al. 2015. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282–95
     [Google Scholar]
  18. 18.
    Jacoby E, Nguyen SM, Fountaine TJ et al. 2016. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7:12320
     [Google Scholar]
  19. 19.
    Gardner R, Wu D, Cherian S et al. 2016. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406–10
     [Google Scholar]
  20. 20.
    Plaks V, Rossi JM, Chou J et al. 2021. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138:1081–85
     [Google Scholar]
  21. 21.
    Hamieh M, Dobrin A, Cabriolu A et al. 2019. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568:112–16
     [Google Scholar]
  22. 22.
    Olson M, Luetkens T, Atanackovic D. 2021. CD19 loss by CAR T cell mediated trogoctyosis is regulated by CAR affinity. J. Immunol. 206:58.03
     [Google Scholar]
  23. 23.
    Spiegel JY, Patel S, Muffly L et al. 2021. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27:1419–31
     [Google Scholar]
  24. 24.
    Fry TJ, Shah NN, Orentas RJ et al. 2018. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24:20–28
     [Google Scholar]
  25. 25.
    Shalabi H, Kraft IL, Wang HW et al. 2018. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 103:e215–18
     [Google Scholar]
  26. 26.
    Schneider D, Xiong Y, Roy A et al. 2015. Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR). J. Immunol. Ther. Cancer 3:P122
     [Google Scholar]
  27. 27.
    Shah NN, Maatman T, Hari P, Johnson B 2019. Multi targeted CAR-T cell therapies for B-cell malignancies. Front. Oncol. 9:146
     [Google Scholar]
  28. 28.
    Wei J, Han X, Bo J, Han W 2019. Target selection for CAR-T therapy. J. Hematol. Oncol. 12:62
     [Google Scholar]
  29. 29.
    Grada Z, Hegde M, Byrd T et al. 2013. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2:e105
     [Google Scholar]
  30. 30.
    Tedder TF, Engel P. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15:450–54
     [Google Scholar]
  31. 31.
    Feugier P. 2015. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Future Oncol 11:1327–42
     [Google Scholar]
  32. 32.
    Cang S, Mukhi N, Wang K, Liu D 2012. Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. Oncol. 5:64
     [Google Scholar]
  33. 33.
    Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P. 2018. An evidence-based review of anti-CD20 antibody-containing regimens for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, or follicular lymphoma. Clin. Lymphoma Myeloma Leuk. 18:508–18.e14
     [Google Scholar]
  34. 34.
    Clark EA, Giltiay NV. 2018. CD22: a regulator of innate and adaptive B cell responses and autoimmunity. Front. Immunol. 9:2235
     [Google Scholar]
  35. 35.
    Barrena S, Almeida J, Yunta M et al. 2005. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19:1376–83
     [Google Scholar]
  36. 36.
    Hassanein NM, Alcancia F, Perkinson KR et al. 2009. Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors (“hematogones”) and B lymphoblastic leukemia blasts. Am. J. Clin. Pathol. 132:573–80
     [Google Scholar]
  37. 37.
    D'Arena G, Musto P, Cascavilla N et al. 2001. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 42:109–14
     [Google Scholar]
  38. 38.
    Dornan D, Bennett F, Chen Y et al. 2009. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114:2721–29
     [Google Scholar]
  39. 39.
    Gardner R, Annesley C, Finney O et al. 2018. Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia. Blood 132:278
     [Google Scholar]
  40. 40.
    Zah E, Lin MY, Silva-Benedict A et al. 2016. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4:498–508
     [Google Scholar]
  41. 41.
    Tong C, Zhang Y, Liu Y et al. 2020. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 136:1632–44
     [Google Scholar]
  42. 42.
    Martyniszyn A, Krahl AC, Andre MC et al. 2017. CD20-CD19 bispecific CAR T cells for the treatment of B-cell malignancies. Hum. Gene Ther 28:1147–57
     [Google Scholar]
  43. 43.
    Shah NN, Johnson BD, Schneider D et al. 2020. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26:1569–75
     [Google Scholar]
  44. 44.
    Zhang Y, Wang Y, Liu Y et al. 2022. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial. Leukemia 36:189–96
     [Google Scholar]
  45. 45.
    Qin H, Ramakrishna S, Nguyen S et al. 2018. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol. Ther. Oncolyt. 11:127–37
     [Google Scholar]
  46. 46.
    Zanetti SR, Velasco-Hernandez T, Gutierrez-Aguera F et al. 2022. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Mol. Ther. 30:550–63
     [Google Scholar]
  47. 47.
    Wei G, Zhang Y, Zhao H et al. 2021. CD19/CD22 dual-targeted CAR T-cell therapy for relapsed/refractory aggressive B-cell lymphoma: a safety and efficacy study. Cancer Immunol. Res. 9:1061–70
     [Google Scholar]
  48. 48.
    Zhang Y, Li J, Lou X et al. 2021. A prospective investigation of bispecific CD19/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Front. Oncol. 11:664421
     [Google Scholar]
  49. 49.
    Tholouli E, Osborne W, Bachier C et al. 2020. 890MO phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. Ann. Oncol. 31:S651
     [Google Scholar]
  50. 50.
    Hu Y, Zhang Y, Zhao H et al. 2020. CD19/CD22 dual-targeted chimeric antigen receptor T-cell therapy for relapsed/refractory aggressive B-cell lymphoma: a safety and efficacy study. Blood 136:34
     [Google Scholar]
  51. 51.
    Wang N, Hu X, Cao W et al. 2020. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood 135:17–27
     [Google Scholar]
  52. 52.
    Huang L, Wang N, Cao Y et al. 2018. CAR22/19 cocktail therapy for patients with refractory/relapsed B-cell malignancies. Blood 135:17–27
     [Google Scholar]
  53. 53.
    Cao Y, Xiao Y, Wang N et al. 2021. CD19/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther 27:910.e1–11
     [Google Scholar]
  54. 54.
    Ruella M, Barrett DM, Kenderian SS et al. 2016. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Investig. 126:3814–26
     [Google Scholar]
  55. 55.
    Yan LE, Zhang H, Wada M et al. 2020. Targeting two antigens associated with B-ALL with CD19-CD123 compound Car T cell therapy. Stem Cell Rev. Rep. 16:385–96
     [Google Scholar]
  56. 56.
    Mihara K, Yoshida T, Takei Y et al. 2017. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells. J. Hematol. Oncol. 10:116
     [Google Scholar]
  57. 57.
    Ormhoj M, Scarfo I, Cabral ML et al. 2019. Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19. Clin. Cancer Res. 25:7046–57
     [Google Scholar]
  58. 58.
    Golubovskaya V, Zhou H, Li F et al. 2021. Novel CD37, humanized CD37 and bi-specific humanized CD37-CD19 CAR-T cells specifically target lymphoma. Cancers 13:981
     [Google Scholar]
  59. 59.
    Scarfo I, Ormhoj M, Frigault MJ et al. 2018. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 132:1495–506
     [Google Scholar]
  60. 60.
    Schneider D, Xiong Y, Wu D et al. 2021. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl. Med. 13:eabc6401
     [Google Scholar]
  61. 61.
    Meng Y, Deng B, Rong L et al. 2021. Short-interval sequential CAR-T cell infusion may enhance prior CAR-T cell expansion to augment anti-lymphoma response in B-NHL. Front. Oncol. 11:640166
     [Google Scholar]
  62. 62.
    Zhang W, Yang J, Zhou C et al. 2020. Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells. Blood 135:2425–27
     [Google Scholar]
  63. 63.
    Schneider D, Xiong Y, Wu D et al. 2017. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J. Immunother. Cancer 5:42
     [Google Scholar]
  64. 64.
    Fousek K, Watanabe J, Joseph SK et al. 2021. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 35:75–89
     [Google Scholar]
/content/journals/10.1146/annurev-med-042921-024719
Loading
Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss
Annual Review of Medicine 74, 279 (2023); https://doi.org/10.1146/annurev-med-042921-024719
/content/journals/10.1146/annurev-med-042921-024719
/content/journals/10.1146/annurev-med-042921-024719
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error